INT315802

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.83
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Tst) RNA binding (Tst) plasma membrane (Tst)
Anatomy Link Frequency
B-cell 4
Tst (Mus musculus)
Pain Link Frequency Relevance Heat
vincristine 2 40.96 Quite Low
positron emission tomography 12 5.00 Very Low Very Low Very Low
corticosteroid 6 5.00 Very Low Very Low Very Low
imagery 6 5.00 Very Low Very Low Very Low
palliative 4 5.00 Very Low Very Low Very Low
Paracetamol 2 5.00 Very Low Very Low Very Low
Calcium channel 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 26 100.00 Very High Very High Very High
Lymphatic System Cancer 136 97.98 Very High Very High Very High
Follicular Lymphoma 26 63.48 Quite High
Acute Myeloid Leukemia 26 59.00 Quite High
Thrombocytopenia 16 55.92 Quite High
Neutropenia 10 55.08 Quite High
Toxicity 32 53.28 Quite High
Diffuse Large B-cell Lymphoma 14 32.48 Quite Low
Disease 50 29.84 Quite Low
Syndrome 2 22.76 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore, residual RTX remains in patientsÂ’ serum for three to six months after treatment and could potentially block CD20 binding sites.46 Preclinical studies using human lymphoma cell lines, patient-derived specimens, and mouse xenograft models have shown that prior RTX therapy reduces CD20 binding, tumor-specific localization, and tumor control for 131I-TST.46 Despite this preclinical data, 131I-TST has been shown to be clinically effective in RTX-refractory relapsed low grade B-cell NHL as discussed previously.31 Future clinical studies should help determine whether inclusion of RTX in induction chemotherapy regimens abrogates the incremental therapeutic gain of consolidation 131I-TST found in the studies listed in Table 4.


Positive_regulation (reduces) of Localization (localization) of 131I-TST in B-cell associated with lymphatic system cancer and cancer
1) Confidence 0.32 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.95 Pain Relevance 0
Furthermore, residual RTX remains in patientsÂ’ serum for three to six months after treatment and could potentially block CD20 binding sites.46 Preclinical studies using human lymphoma cell lines, patient-derived specimens, and mouse xenograft models have shown that prior RTX therapy reduces CD20 binding, tumor-specific localization, and tumor control for 131I-TST.46 Despite this preclinical data, 131I-TST has been shown to be clinically effective in RTX-refractory relapsed low grade B-cell NHL as discussed previously.31 Future clinical studies should help determine whether inclusion of RTX in induction chemotherapy regimens abrogates the incremental therapeutic gain of consolidation 131I-TST found in the studies listed in Table 4.


Positive_regulation (reduces) of Localization (localization) of 131I-TST in B-cell associated with lymphatic system cancer and cancer
2) Confidence 0.32 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.88 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox